Clinical trial progress of Rituximab therapy in children with primary nephrotic syndrome
10.3760/cma.j.cn101070-20200809-01315
- VernacularTitle:利妥昔单抗治疗儿童原发性肾病综合征的临床研究进展
- Author:
Zhihong HAO
1
;
Li YU
Author Information
1. 广州市第一人民医院，华南理工大学附属第二医院儿科 510180
- From:
Chinese Journal of Applied Clinical Pediatrics
2020;35(17):1303-1309
- CountryChina
- Language:Chinese
-
Abstract:
Primary nephritic syndrome (PNS) is the most common glomerular disease in children.Glucocorticoid alone or concurrent with immunosuppressive agents is the main treatment for various types of PNS.However, about 20% of children with PNS still show frequent relapse or steroid dependence during or after withdrawal of hormones and/or immunosuppressive agents.For these children, the long-term and high-dose use of hormones and/or immunosuppressive agents cause serious side effects and even intolerance.Additionally, there are 1%-3% children with PNS showing no response to hormones and all immunosuppressive agents, and they need new treatment regiments.In recent 15 years, there have been increasing clinical trials on the treatment of various types of PNS with Rituximab (RTX). The study results show that RTX can prolong the remission period of PNS and reduce the dose and side effects of hormones and immunosuppressive agents.Moreover, some randomized controlled trials revealed that RTX can be used as a potential first-line drug for hormone-dependent or frequently-relapsing PNS or a second-line treatment for hormone-resistant PNS.In this article, the latest clinical trial designs and results of RTX in the treatment of PNS in children in recent years were summarized, so as to provide reference for the clinical practice and research of RTX in the treatment of PNS.
